A randomized controlled clinical trial comparing "guideline exposed" and "guideline naive" physicians in respect to dosage selection and treatment outcome with doxepin in depressive disorders

Pharmacopsychiatry

Volumn 40, Issue 2, 2007, Pages 77-81

  Linden, M ^a   Schotte, K ^b  

^a Rehabilitation Centre Seehof   (Germany)

^b NONE

Author keywords

Doxepin; Drug utilization observation study; Prescribing patterns; Quality assurance; Treatment algorithms; Treatment guidelines; Tricyclic antidepressants

Indexed keywords

DOXEPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOXEPIN; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSYCHIATRY;

EID: 34247892243     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-972574     Document Type: Article

References (43)

1. Adli M, Berghofer A, Linden M, Helmchen H, Muller-Oerlinghausen B, Mackert A, Stamm T, Bauer M: Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiat 2002; 63: 782-790
2. Arzneimittelkommission der Deutschen Ärzteschaft (AKdÄ). Empfehlungen zur Therapie der Depression Arzneiverordnung in der Praxis, Sonderheft 5, AKdÄ, 1997
3. Appleton WS: Fourth psychoactive drug usage guide. J Clin Psychiat 1982; 43: 12-27
4. Azocar F, Cuffel B, Goldmann W, McCarter L: The impact of evidence-based guideline dissemination for the assessment and treatment of major depression in a managed behavioral health care organization. J Behav Health Service Res 2003; 30: 109-118
5. Bridges PK: "...and a small dosage of an antidepressant might help". Brit J Psychiat 1983; 142: 626-628
6. Choudhry NK, Stelfox HAT, Detsky AS: Relationship between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617
7. Dimascio A, Meyer RE, Stifler L: Effects of Imipramine on individuals varying in level of depression. Am J Psychiat 1968; 124: 55-58
8. Donoghue JA, Tylee A: The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Brit J Psychiat 1996; 168: 164-168
9. Donoghue JA, Tylee A, Wildgust H: Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom. Brit Med J 1996; 313: 861-862
10. Furukawa TA MH, Barbui C: Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. Brit Med J 2002; 325: 991-999
11. Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J: Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta psychiat scan 2005; 112: 425
12. Helmchen H, Linden M, (Guest Editors): Subthreshold disorders in psychiatry. Comprehens Psychiat 2000; 41: 1-137
13. Ito H, Koyama A, Higuchi T: Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Brit J Psychit Brit J Psychiat tr 2005; 187: 243-247
14. Jerling M: Dosing of antidepressants - The unknown art. J Clin Psychopharmacol 1995; 15: 435-439
15. Kjaergard LL, Als-Nielsen B: Association between competing interests and authors' conclusions: epidemiological study of randomized clinical trials published in the BMJ. Brit Med J 2002; 325: 249
16. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB: Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. neuropsychopharmacology 2005; 30: 445-460
17. Linden M: Der Einfluss von Leitlinien, Standards und ökonomischen Vorgaben auf medizinische Entscheidungsprozesse. Z ärztl Fortbild Qualität Gesundheitswesen 2004; 98: 200-205
18. Linden M: Leitlinien und die Psychologie medizinischer Entscheidungsprozesse bei der Behandlung depressiver Erkrankungen. Fortsch Neurol Psychiat 2005; 73: 249-258
19. Linden M, Schuessler G: Low dosage antidepressant treatment in private practice - a replication study. Pharmacopsychiatry 1985; 18: 44-45
20. Linden M, Helmchen H, Mackert A, Müller-Oerlinghausen B: Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed patients. Pharmacopsychiatry 1994; 27: 51-53
21. Linden M, Ahrens B, Schotte K, Golde J: Der Einfluß von Richtlinien-empfehlungen auf die Niedrigdosierung trizyklischer Antidepressiva am Beispiel von Doxepin. Psychopharmakotherapie 2000; 7: 75-79
22. Linden M, Ludewig K, Munz T: Depressive Erkrankungen und antidepressive Therapie. Ein Vergleich von Nervenarztpraxis und psychiatrischer Klinik. Nervenarzt 2001; 72: 521-528
23. Linden MLK, Munz T, Dierkes W: Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients. Results of a drug utilization observation study. Pharmacopsychiatry 2003; 36: 197-205
24. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS et al: The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a medicaid population. J Clin Psychiat 1990; 51: 60-69
25. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG: Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland. Brit Med J 1996; 313: 860-861
26. Munizza C, Tibaldi G, Bollini P, Pirfo E, Punzo F, Gramaglia F: Prescription pattern of antidepressants in outpatient psychiatric practice. Psychol Med 1995; 25: 771-778
27. Nunn CMH: Efficacy of antidepressant medication. Brit J Psychiat 2003; 183: 463-464
28. Paykel ES HJ, Freeling P et al: Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial. J Affect Disord 1988; 14: 83-95
29. Paykel ES, Priest RG: Recognition and management of depression in general practice: consensus statement. Brit Med J 1992; 305: 1198-1202
30. Perils RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M: Clinical and sociodemographic predictors of response to augmentation or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta psychiat scand 2003; 108: 432-438
31. Pincus HA, Marcus SC, Olfson M, Zarin DA, Thompson J: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 1998;279
32. Rao ML, Deister A, Laux G et al: Low serum levels of tricyclic antidepressants in Amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with non-response. Pharmacopsychiatry 1996; 29: 97-102
33. Schaaf B, Linden M, Weber HJ: An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study. Pharmacopsychiatry 1997; 30: 44-51
34. Schneider F, Harter M, Brand S, Sitta P, Menke R, Hammer-Filipiak U, Kudling R, Heindl A, Herold K, Frommberger U, Elmer O, Hetzel G, Witt G, Wolfersdorf M, Berger M, Gaebel W: Adherence to guidelines for treatment of depression in in-patients. Brit J Psychiat 2005; 187: 462-469
35. Schotte K, Linden M: Reasons for low-dosage treatment with antidepressants by psychiatrists and general practitioners. J Pharmacoepidem Drug Safety 2007, ; in press
36. Stewart JW, Quitkin FM, Klein DF: The pharmacotherapy of minor depression. Am J Psychother 1992; 46: 23-26
37. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stuart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackheim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. A STAR*D report. Am J Psychiat 2006; 163: 1905-1917
38. Thiels C, Linden M, Grieger F, Leonhard J: Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 2005; 20: 1-7
39. Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes T, Rush AJ: Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiat 2006; 67: 1362-1372
40. Verdoux H, Begaud B: Pharmaco-epidemioloy: What do (and don't) we know about utilization and impact of psychotropic medications in real life conditions. Brit J Psychiat 2004; 185: 93-94
41. Wang PS, Schneeweiss S, Brookhart MA, Glynn RJ, Mogun H, Patrick AR, Avorn J: Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol 2005; 25: 118-126
42. Weiner J, Schumacher G: Psychotropic drug therapy knowledge of health care practitioners. Am J Hosp Pharm 1976; 33: 237-241
43. World Health Organisation. Dosage effects of antidepressant medication in different populations A World Health organisation Collaborative Study. J Affect Disord 1986;1-67